HCA Healthcare reported a $150 million revenue hit in Q1 2026 directly attributed to the lapse in Affordable Care Act subsidies—a figure that translates to roughly 100,000 patient visits at typical reimbursement rates. The nation's largest for-profit health system just quantified what most marketing

The FDA's March 26, 2026 approval of Kresladi (marnetegragene autotemcel) for severe Leukocyte Adhesion Deficiency Type I marks a turning point not just for pediatric immunology, but for how rare disease marketers must operate. Rocket Pharmaceuticals now holds the first-ever FDA-approved gene therap

The FDA just approved a gene therapy for genetic hearing loss in 61 days—tied for the fastest biologics license application approval in modern agency history. For healthcare marketers in the rare disease and precision medicine space, this velocity changes patient identification timelines, reimbursem

The FDA's decision in early 2026 to back three psychedelic drug studies for mental illness treatment marks the clearest regulatory signal yet that psychedelic-assisted therapy is on a trajectory toward mainstream clinical use , and healthcare systems that wait for full approval before building their

CMS announced in 2026 its intent to require states to conduct audits of Medicaid-enrolled providers, according to reporting from Becker's Hospital Review [1]. While the regulatory machinery is still being assembled , state implementation timelines, audit scope, and enforcement thresholds remain subj

The slowdown in National Institutes of Health grant awards accelerating into 2026 is doing more than shrinking research budgets , it is restructuring the competitive landscape for academic medical centers, community hospitals, and specialty practices that built patient acquisition strategies around

UnitedHealth Group raised its 2026 profit outlook following first-quarter earnings that exceeded Wall Street expectations, extending the nation's largest health insurer's financial outperformance at a moment when providers face margin pressure from real estate costs, regulatory compliance, and reimb

The most consequential psychedelic therapy conversation of 2026 is not about psilocybin or ketamine , it is about ibogaine, a Schedule I substance derived from the African iboga plant that is attracting serious federal attention for its potential to treat opioid use disorder (OUD). As the FDA naviga

The FDA's accelerated push to streamline biosimilar development and expand state drug importation programs in 2026 has opened a marketing opportunity most health systems haven't recognized: affordability messaging now belongs at the center of patient acquisition strategy, not buried in financial ass

A presidential executive order in April 2026 loosening restrictions on psychedelic drugs creates the first legitimate marketing opportunity for a substance class that has lived in regulatory limbo for half a century. Healthcare organizations and pharmaceutical companies now face a market with millio